Forma Therapeutics Holdings, Inc.
Forma Therapeutics Holdings, Inc. (FMTX): 6 pipeline candidates · ~26 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
26.2 months
D/E 0.15 · 0% dilution
Lead: Phase 2/Phase 3
6 candidates
N/A
N/A
A transparent, data-derived signal for Forma Therapeutics Holdings, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$77.3M
Quarterly Burn
$44.8M
Runway
26.2 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
Frequently asked questions
How many drug candidates are in Forma Therapeutics Holdings, Inc.'s pipeline?
Forma Therapeutics Holdings, Inc. (FMTX) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Forma Therapeutics Holdings, Inc.'s lead drug candidate?
Forma Therapeutics Holdings, Inc.'s most advanced tracked candidate is etavopivat (Phase 2) for Sickle Cell Disease; Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R.
What is Forma Therapeutics Holdings, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Forma Therapeutics Holdings, Inc. has approximately 26.2 months of cash runway.
Who is the CEO of Forma Therapeutics Holdings, Inc.?
Frank D. Lee is the chief executive officer of Forma Therapeutics Holdings, Inc. (FMTX).
Get the full picture on Forma Therapeutics Holdings, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.